Updates on Hepion Pharmaceuticals' ASCEND-NASH Trial, now in wind-down phase. Explore insights into Phase 2b study progression and strategic alternatives.
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis ("NASH"), hepatocellular carcinoma ("HCC"), and other chronic